

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT								
NATURE OF CONVEYANCE:	ASSIGNMENT								
CONVEYING PARTY DATA									
<table border="1"> <thead> <tr> <th>Name</th> <th>Execution Date</th> </tr> </thead> <tbody> <tr> <td>Mark Abelson</td> <td>03/09/2012</td> </tr> <tr> <td>Angel Padilla</td> <td>03/09/2012</td> </tr> <tr> <td>Kirk McMullin</td> <td>03/23/2012</td> </tr> </tbody> </table>		Name	Execution Date	Mark Abelson	03/09/2012	Angel Padilla	03/09/2012	Kirk McMullin	03/23/2012
Name	Execution Date								
Mark Abelson	03/09/2012								
Angel Padilla	03/09/2012								
Kirk McMullin	03/23/2012								
RECEIVING PARTY DATA									
Name:	ISTA Pharmaceuticals, Inc.								
Street Address:	50 Technology Drive								
City:	Irvine								
State/Country:	CALIFORNIA								
Postal Code:	92618								
PROPERTY NUMBERS Total: 1									
<table border="1"> <thead> <tr> <th>Property Type</th> <th>Number</th> </tr> </thead> <tbody> <tr> <td>Application Number:</td> <td>13369452</td> </tr> </tbody> </table>		Property Type	Number	Application Number:	13369452				
Property Type	Number								
Application Number:	13369452								
CORRESPONDENCE DATA									
Fax Number:	(404)541-2905								
Email:	ipdocket@thompsonhine.com								
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent via US Mail.</i>									
Correspondent Name:	Beverly A. Lyman								
Address Line 1:	3560 Lenox Road								
Address Line 2:	Suite 1600								
Address Line 4:	Atlanta, GEORGIA 30329								
ATTORNEY DOCKET NUMBER:	078807.28								
NAME OF SUBMITTER:	Beverly A. Lyman								
Total Attachments: 2 source=Assignment_ISTA28#page1.tif source=Assignment_ISTA28#page2.tif									

OP \$40.00 13369452


ASSIGNMENT OF INVENTION AND PATENTS THEREON

WHEREAS, we, Mark Abelson of 26 Philips Street, Andover, MD 01810; and Angel Padilla of 60 Deerborn Drive, Aliso Viejo, CA 92656 have invented OPTHALMIC FORMULATIONS AND USES THEREOF as fully disclosed in U.S. Application No. 13/369,452, filed February 9, 2012, claiming priority to U.S. Application No. 11/146,652, filed June 7, 2005; U.S. Provisional Application No. 60,675,179, filed April 26, 2005; and U.S. Provisional Application No. 60/577,567, filed June 7, 2004 preparatory to obtaining Letters Patent therefor.

WHEREAS, ISTA Pharmaceuticals, Inc., a corporation organized under the Laws of the State of Delaware and having its principal office at 50 Technology Drive, Irvine, CA 92618 desires to acquire the entire interest in and to the subject-matter disclosed in said application and in and to all patents issued or to be issued thereon;

NOW, THEREFORE, to all whom it may concern, be it known that, for and in consideration of the sum of One Dollar to each of us in hand paid, and other good and valuable consideration, the receipt of which is hereby acknowledged, we, Mark Abelson and Angel Padilla have sold, assigned and transferred, and by these presents does sell, assign and transfer unto ISTA Pharmaceuticals, Inc. our entire right, title and interest in and to all Letters and in and to the subject matter disclosed therein, and any continuations, divisions, renewals, substitutes or reissues thereof, and in and to all Letters Patent Domestic and Foreign issued or to be obtained thereon, including all rights and interests with priority rights under the Paris Convention for the Protection of Industrial Property, the International Patent Cooperative Union, European Patent Convention, Common Market Convention, or any other Convention or Union for each country of said Convention or Union; and we do hereby authorize and request the Commissioner of Patents to issue the Letters Patent granted on the application and all future patents granted upon the subject matter disclosed therein to the above-named Assignee, its legal representatives and assigns.

Witness my hand this 9 day of March, 2012.


Mark Abelson

Witness my hand this 9 day of March, 2012.


Angel Padilla

843097.1

ASSIGNMENT OF INVENTION AND PATENTS THEREON

WHEREAS, I, Kirk McMullin of 18692 Valencia Circle, Villa Park, CA 92861 have invented OPTHALMIC FORMULATIONS AND USES THEREOF as fully disclosed in U.S. Application No. 13/369,452, filed February 9, 2012, claiming priority to U.S. Application No. 11/146,652, filed June 7, 2005; U.S. Provisional Application No. 60/675,179, filed April 26, 2005; and U.S. Provisional Application No. 60/577,567, filed June 7, 2004 preparatory to obtaining Letters Patent therefor.

WHEREAS, ISTA Pharmaceuticals, Inc., a corporation organized under the Laws of the State of Delaware and having its principal office at 50 Technology Drive, Irvine, CA 92618 desires to acquire the entire interest in and to the subject-matter disclosed in said application and in and to all patents issued or to be issued thereon;

NOW, THEREFORE, to all whom it may concern, be it known that, for and in consideration of the sum of One Dollar in hand paid, and other good and valuable consideration, the receipt of which is hereby acknowledged, I, Kirk McMullin, have sold, assigned and transferred, and by these presents does sell, assign and transfer unto ISTA Pharmaceuticals, Inc. my entire right, title and interest in and to all Letters and in and to the subject matter disclosed therein, and any continuations, divisions, renewals, substitutes or reissues thereof, and in and to all Letters Patent Domestic and Foreign issued or to be obtained thereon, including all rights and interests with priority rights under the Paris Convention for the Protection of Industrial Property, the International Patent Cooperative Union, European Patent Convention, Common Market Convention, or any other Convention or Union for each country of said Convention or Union; and I do hereby authorize and request the Commissioner of Patents to issue the Letters Patent granted on the application and all future patents granted upon the subject matter disclosed therein to the above-named Assignee, its legal representatives and assigns.

Witness my hand this 23RD day of MARCH, 2012


Kirk McMullin